Literature DB >> 7623012

Molecular and serologic analysis in the transmission of the GB hepatitis agents.

G G Schaluder1, G J Dawson, J N Simons, T J Pilot-Matias, R A Gutierrez, C A Heynen, M F Knigge, G S Kurpiewski, S L Buijk, T P Leary.   

Abstract

Two flavivirus-like genomes have recently been cloned from infectious tamarin (Saguinus labiatus) serum, derived from the human viral hepatitis GB strain, which is known to induce hepatitis in tamarins. In order to study the natural history of GB infections, further transmission studies were carried out in tamarins. Reverse-transcription-polymerase chain reaction and enzyme-linked immunosorbant assays were developed for the detection of RNA and antibodies associated with the two agents, GB virus-A and GB virus-B. The infectivity of both of these agents was demonstrated in tamarins to be filterable through a 0.1 micron filter. Two distinct genomes were identified in the serum of eight of the infected tamarins, while in four tamarins, the genomes were detected independently of each other. Although specific antibodies to the GB virus-B epitopes were detected in the serum of animals inoculated with both agents or GB virus-B alone, antibodies to putative epitopes specific to GB virus-A were not detected in any of the animals. All tamarins inoculated with serum containing GB virus-B exhibited an elevation in liver enzyme levels after inoculation. Elevations of serum liver enzyme levels did not occur when GB virus-A was the only agent detected in the serum. Infection with the original infectious tamarin inoculum conferred protection from reinfection with GB virus-B but not with GB virus-A.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623012     DOI: 10.1002/jmv.1890460117

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  38 in total

1.  Partial sequencing of 5' noncoding region of 7 HGV strains isolated from different areas of China.

Authors:  Xing-Tai Wang; Hui Zhuang; Hai-Bo Song; He-Min Li; Hua-Yuan Zhang; Yang Yu
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

2.  Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus.

Authors:  B Beames; D Chavez; B Guerra; L Notvall; K M Brasky; R E Lanford
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  A B C d e f g ...

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1996-05

4.  Translation initiation in GB viruses A and C: evidence for internal ribosome entry and implications for genome organization.

Authors:  J N Simons; S M Desai; D E Schultz; S M Lemon; I K Mushahwar
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 5.  Immunodiagnosis of viral hepatitides A to E and non-A to -E.

Authors:  G Yang; G N Vyas
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

6.  Species-specific variants of GB virus A in captive monkeys .

Authors:  T P Leary; S M Desai; J Yamaguchi; M L Chalmers; G G Schlauder; G J Dawson; I K Mushahwar
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Hepatitis--how far down the alphabet?

Authors:  J N Zuckerman
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

Review 8.  Murine models of hepatitis C: what can we look forward to?

Authors:  Markus von Schaewen; Alexander Ploss
Journal:  Antiviral Res       Date:  2014-01-24       Impact factor: 5.970

9.  GBV-C RNA presence in several high-risk groups of Spain.

Authors:  E Quirós; G Piédrola; M C Maroto
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

10.  Identification of GBV-D, a novel GB-like flavivirus from old world frugivorous bats (Pteropus giganteus) in Bangladesh.

Authors:  Jonathan H Epstein; Phenix-Lan Quan; Thomas Briese; Craig Street; Omar Jabado; Sean Conlan; Shahneaz Ali Khan; Dawn Verdugo; M Jahangir Hossain; Stephen K Hutchison; Michael Egholm; Stephen P Luby; Peter Daszak; W Ian Lipkin
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.